Posted tagged ‘Dr. Lindsay Rosenwald’

Several Factors Combine to Lift Biotech Industry

March 31, 2014



Last year saw a number of strong performances in the biotechnology industry as the sector benefited from several overall trends. In the past, many fund managers avoided biotechnology, as it requires specialized knowledge and a strong tolerance for risk. Managers fleeing a weakening mining sector and trying to dodge the falling price of gold, however, took to biotechnology in 2013, just as companies were posting startling gains.




Several small international firms saw their share prices rise by multiples of up to six, while others raised tens of millions of dollars in capital or successfully navigated initial public offerings. Executives with histories of success took the helms of several businesses, and in the fourth quarter, the biotech market rose to yearlong highs. In the United States, the market turned around after poorly performing for several years. Biotech companies able to find new funding in 2013 did so on the back of prospects for treatments in a variety of areas, including Alzheimer’s disease, regenerative medicine, and infectious diseases.

What to Consider Before Seeking Venture Capital

December 2, 2013

Dr. Lindsay Rosenwald maintains expertise in several areas of finance, from direct investing to venture capital. Today, many entrepreneurs, like Dr. Lindsay Rosenwald, turn to venture capitalists for the money they need to realize their ideas. Before seeking funding, however, they must consider several factors.

First, entrepreneurs must have a clear market for their product and be able to demonstrate to investors how and why the product or service will generate money. Some ideas that sound great on paper simply lack a viable market, thus making them unlikely to receive funding. Additionally, the market must be large enough to attract substantial revenue. Venture investors typically look for markets of a certain size before they will even consider putting money into a new idea.

Entrepreneurs should gather a team of experienced, knowledgeable managers capable of developing the envisioned business, particularly when asking for funding at a later stage of the enterprise. When leaders can point to the past successes of team members and clearly spell out their contribution to the current project, they will more likely convince a venture capitalist to invest in the plan.

FDA Recognizes Need for Patient-Centric Drug Development

September 20, 2013

Over the last two decades, Dr. Lindsay Rosenwald has founded and invested in an array of biotechnology start-ups, funding research and development for drugs to treat leukemia and prostate cancer. Today, Dr. Lindsay Rosenwald serves as a founding partner at an investment partnership in New York City.

Recently, the New England Journal of Medicine published an article discussing the need for more patient-centered drug development, specifically surrounding cancer treatment therapies. Physicians report that patients often ask how medications will make them feel, yet clinical trial data rarely includes patient accounts of how the drug affected their everyday lives. Thanks to advanced drugs and therapies, patients are often able to live longer with a disease; these advances only increase the importance of reporting on how a certain drug affects the patient’s quality of life.

Additionally, the U.S. Food and Drug Administration has recognized that drug developers often focus on a drug’s end result without taking the patient’s perspective into consideration. The agency has started taking steps to alleviate this challenge, but the aforementioned article recommends that the FDA raise its standards even higher. The New England Journal of Medicine’s commentator suggests identifying patient-centered outcomes and metrics during the earliest stages of drug development and using them to analyze patient feedback throughout pivotal trials. He believes that adopting this process could help improve quality of life for thousands of cancer patients.

Dr. Lindsay Rosenwald: Understanding the Symptoms of Schizophrenia

April 29, 2013

Schizophrenia affects some 2.4 million adults over 18 in the United States in any given year. This chronic condition is defined as a serious brain disorder in which patients are unable to interpret reality adequately. The condition can produce hallucinations, distorted mental processes, delusional thoughts, and maladaptive behavior. Although a number of effective pharmacological and psychological treatments exist that can alleviate symptoms, individuals with schizophrenia typically require lifelong medical support.

Males and females exhibit symptoms of schizophrenia in equal numbers. Men most often manifest the disorder in their late teens or at the beginning of their 20s; onset in women typically occurs in their 20s or early 30s. Children and people past their mid-40s seldom receive initial diagnoses of schizophrenia.

Among the symptoms of schizophrenia are reduced capacity for long-range planning, withdrawal from social life and customary activities, diminished motivation, lack of attention to hygiene and grooming, apparent flattening of emotional affect, and suicidal thoughts. People with schizophrenia often have trouble processing and understanding information, remembering, and focusing attention. Because a certain amount of withdrawal, irritability, and emotional volatility often occur during adolescence, diagnosing schizophrenia in teens can be problematic. Teens with schizophrenia are more apt to experience visual hallucinations and less prone to exhibit delusions than adult patients.

If you suspect someone you know has from schizophrenia, urge him or her to seek professional medical assistance. Many individuals who experience the disorder lack the ability to understand the serious nature of their situation. Appropriate medication and a strong support network can make a tremendous difference in the quality of life for individuals with schizophrenia.

The founder or co-founder of several biotechnology and investment companies, Dr. Lindsay Rosenwald has been instrumental in successfully bringing to market medications to treat schizophrenia, rheumatoid arthritis, cancer, and other serious conditions.

Acute Promyelocytic Leukemia Patients Now Have Hope

April 22, 2013

In 2000, the United States Food and Drug Administration approved a drug developed through a small biopharmaceutical start-up company developed by Dr. Lindsay Rosenwald as a treatment for acute promyelocytic leukemia. The drug, arsenic trioxide, has since won the confidence of a variety of physicians who treat the disease, and studies have found it to produce long-term remission in a significant sample of patients who received it.

Acute promyelocytic leukemia, a type of acute myeloid leukemia, is a cancer centered in the bone marrow. APL causes the growth of promyelocytes, or immature white blood cells, which then crowd out the healthy white blood cells that battle infection, the oxygen-transporting red blood cells, and the clotting agents known as thrombocytes, or platelets.

APL patients typically display an increased tendency to anemia, nosebleeds, bleeding gums, bruising, and other conditions that indicate excessive blood loss. The growing cancer cells, combined with the diminished number of healthy blood cells, additionally contribute to overall fatigue, slow wound-healing, and joint and bone pain.

According to the journal Leukemia, arsenic trioxide is the drug most frequently indicated in the treatment of APL. Dr. Lindsay Rosenwald and his team devoted considerable resources to their development of the drug, after numerous other investors and pharmaceutical analysts had dismissed it. Dr. Rosenwald has served as a practicing physician and an investment professional in the highly competitive Wall Street biotechnology sector. He has funded or created companies whose work has been instrumental in developing medications to treat not only cancer but rheumatoid arthritis, schizophrenia, fibromyalgia, and obesity.

[Sources: http://www.ucsfhealth.org/conditions/acute_myeloid_leukemia/signs_and_symptoms.html
http://ghr.nlm.nih.gov/condition/acute-promyelocytic-leukemia
http://www.ncbi.nlm.nih.gov/pubmed/21904379 ]

Lindsay Rosenwald: Some Basic Information About Rheumatoid Arthritis

April 15, 2013

Rheumatoid arthritis, a chronic autoimmune disorder, affects about 1 percent of the American population. Women are three times as likely as men to develop the condition.

In rheumatoid arthritis, the lining of a patient’s joints becomes inflamed. The disorder often involves the skin, eyes, lungs, and heart, as well as the nervous and circulatory systems. The patient’s body comes under attack from his or her own immune system, which mistakenly targets healthy organs and tissues as if they were diseased. Symptoms include pain, swelling, and feelings of extreme warmth, usually in symmetrical parts of the body such as knees or wrists. Individuals who suffer from RA may additionally experience feelings of stiffness, fever, or long-lasting exhaustion. While some patients notice a rapid onset and progression of symptoms, the disease moves forward gradually in others.

Most people who develop rheumatoid arthritis first experience symptoms in their 30s, 40s, or 50s, but it can manifest at any age. The condition occurs more frequently in smokers and those with an affected family member. If not treated successfully, RA can produce swelling that wears away bone and deforms joints.

The key to slowing the progression of RA is early and aggressive intervention. Treatments concentrate on relieving symptoms and preventing serious damage to the joints.

Dr. Lindsay Rosenwald, a successful Wall Street investor in the biotechnology industry and a physician formerly in practice in Philadelphia, has established and funded a variety of start-up biotechnology companies. Companies he has funded have been instrumental in developing medications that target rheumatoid arthritis, cancer, fibromyalgia, and other diseases.